Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Analysis of the Immune Parameters Involved in the Onset and Fate of SARS-CoV-2 Infection in Patients With Multiple Myeloma (COVIMMUNOMM) COVID-19 and Multiple Myeloma

NCT04805203 is registered in ClinicalTrials.gov with Intergroupe Francophone du Myelome as lead sponsor.

NCT NCT04805203
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04805203 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Analysis of the Immune Parameters Involved in the Onset and Fate of SARS-CoV-2 Infection in Patients With Multiple Myeloma (COVIMMUNOMM) COVID-19 and Multiple Myeloma
Lead sponsor
Intergroupe Francophone du Myelome
Phase
Not applicable
Overall status
Terminated
Start date
December 16, 2020
Completion date
December 31, 2022
Enrollment
139 (actual)
Sites
53

Conditions

As the registry lists them; a condition with its own page is linked.

covid19, multiple myeloma